Literature DB >> 2418296

Hemodynamic effects of nicorandil, isosorbide dinitrate, and dihydralazine in healthy volunteers.

G G Belz, J H Matthews, A Beck, G Wagner, B Schneider.   

Abstract

In this randomized, double-blind, crossover, single-dose study with 12 healthy subjects, we determined the hemodynamic changes and their time kinetics after administration of the mononitrate nicorandil (60 mg s.l.) and compared these effects with changes after administration of isosorbide dinitrate (ISDN; 20 mg s.l.), dihydralazine (10 mg i.v.), and placebo. Mechanocardiography, electrical impedance cardiography, and M-mode echocardiography measured drug effects. Dihydralazine increased heart rate, systolic pressure, and ventricular ejection time, and it decreased peripheral resistance, diastolic pressure, preejection period, end-systolic diameter and wall stress; these changes indicate an intense, pure afterload reduction. ISDN decreased systolic pressure, peripheral resistance, end-diastolic and systolic diameters and wall stress, shortened the ejection time, and prolonged the preejection period. The responses suggest ISDN causes a notable preload reduction accompanied by some afterload reduction. Nicorandil's effects were similar to those of ISDN in that the reductions in preload were equal, although the afterload reduction was more intense. Nicorandil's effects reached significance within 10 min, reached a maximum by 60 min, and had not vanished at 4 h. A drug with this profile and time kinetics should be tested further in situations requiring pre- and afterload reductions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2418296     DOI: 10.1097/00005344-198511000-00015

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

1.  Differential cardiovascular effects of propranolol, atenolol, and pindolol measured by impedance cardiography.

Authors:  S H Thomas; R C Cooper; M Ekwuru; S Fletcher; J Gilbody; T S Husseyin; M Ishaque; R Jagathesan; G Reddy; S E Smith
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Electrophysiologic effects of potassium channel openers.

Authors:  W Haverkamp; M Borggrefe; G Breithardt
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

Review 3.  Systolic time intervals in clinical pharmacology.

Authors:  Q Li; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  Pharmacology and therapeutic effects of nicorandil.

Authors:  M Kinoshita; K Sakai
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

5.  A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris.

Authors:  S Di Somma; V Liguori; M Petitto; A Carotenuto; D Bokor; O de Divitiis; M de Divitiis
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

Review 6.  Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.

Authors:  J Frampton; M M Buckley; A Fitton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

7.  The haemodynamic effects and pharmacokinetics of intravenous nicorandil in healthy volunteers.

Authors:  D L Wolf; J J Ferry; A E Hearron; M O Froeschke; J R Luderer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Acute and subacute effects of nicorandil and isosorbide dinitrate on vessel wall properties of large arteries and hemodynamics in healthy volunteers.

Authors:  M J Kool; J J Spek; H A Struyker Boudier; A P Hoeks; R S Reneman; R H van Herwaarden; L M Van Bortel
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

9.  Differential effects of the novel NO-donating drug pirsidomine and isosorbide dinitrate on the venous vascular bed.

Authors:  C de Mey; K Breithaupt; M Seibert-Grafe; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

10.  The pharmacokinetics and haemodynamic effects of continuous nicorandil infusion in healthy volunteers.

Authors:  D L Wolf; A E Hearron; C M Metzler; J J Ferry; M O Froeschke; J R Luderer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.